Atrium Therapeutics, Inc.
RNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002093101
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $192.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $162.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −8 vs. previous quarter
- 154
- 13F valueReported value at the end of Q2 2026
- $192.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- $15.3M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.75M
- Shares sold short
- Change
- +22.9K
- +0.6% vs. previous
- Days to cover
- 16.07
- At average daily volume
Superinvestors holding RNA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding RNA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Atrium Therapeutics, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
See all 154 holdersThe largest institutional positions in Atrium Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | $20.2M | 0.35% | +948,609+172.0% | Added |
| Price T Rowe Associates Inc | 1,472,984 | $19.8M | 0.00% | −80,226−5.2% | Reduced |
| BlackRock, Inc. | 1,447,476 | $19.5M | 0.00% | +242,185+20.1% | Added |
| Vanguard Capital Management LLC | 730,831 | $9.83M | 0.00% | +103,962+16.6% | Added |
| CRCM LP | 641,539 | $8.63M | 5.67% | +641,539 | New |
| TIG Advisors, LLC | 561,533 | $7.55M | 0.35% | −46,019−7.6% | Reduced |
| Geode Capital Management, LLC | 386,929 | $5.21M | 0.00% | +67,098+21.0% | Added |
| Two Sigma Investments, LP | 345,481 | $4.65M | 0.00% | +166,921+93.5% | Added |
| Goldman Sachs Group Inc | 310,341 | $4.17M | 0.00% | −39,609−11.3% | Reduced |
| 683 Capital Management, LLC | 300,000 | $4.04M | 0.37% | 00.0% | Unchanged |
Holders of 5% or more of RNA
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Atrium Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 13G | 8.80%1.50M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Price T Rowe Associates Inc | 13G/A | 8.60%1.47M shares | −1.40 ppfrom 10.00% | Apr 8, 20262 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%1.14M shares | +1.40 ppfrom 5.20% | Apr 27, 20262 filings | Jul 27, 2026 | SEC |